lesions, have a specific initiation pattern under MRI (MRILIP) consisting in showing Gadolinium enhancement before FLAIR MRI appearance. Under 7-Tesla MRI Ball lesions show a center vein, like in MS. Treatment Treatment with corticosteroids is usual to relieve inflammation. Epidemiology The disease is more common in Chinese and Filipino populations (both Asiatic) than in caucasoids. Balo-like lesions have been reported to appear also in Tumefactive inflammatory leukoencephalopathy Associations A possible association with psoriasis and autoimmune thyroiditis has been reported Pattern III (Baló-like) demyelinating spectrum Baló-like lesions were classified as MS lesion pattern III in the MS spectrum. They have been reported alone, but also associated to standard multiple sclerosis, neuromyelitis optica, CADASIL and progressive multifocal leukoencephalopathy There is an overlap between what is considered Baló concentric sclerosis and some atypical cases of multiple sclerosis. A special subtype of multiple sclerosis presents Baló-like lesions (pattern III lesions) creating an intersection between these two conditions. Some patients with BCS present oligoclonal bands while others do not. It has been proposed that BCS lesions may not denote a single disease, but a final pathway of various demyelinating diseases, reflecting the presence of intralesional hypoxia as recently proposed Recently it has been reported that pattern III lesions are responsive to Mitoxantrone. On the other hand, this pattern is the less responsive to plasmapheresis Pattern III lesions can be diagnosed without a biopsy because these patients show a high reactivity to AQP1 (without antibody) and varicella zoster virus (VZV). Origin of the lesions Pattern III lesions were for sometime thought to be a MS nascent lesion, though it is not likely anymore. A strain of bacterium Clostridium perfringens has been found in Pattern III lesions. Tests in mice found that a toxin made by a rare strain of C. perfringens caused MS-like damage in the brain, and earlier work had identified this strain of C. perfringens in a human with MS. MS patients were found to be 10 times more immune-reactive to the epsilon toxin than healthy people. Later reports state that Baló's patients showed loss of AQP1 and AQP4 in demyelinating lesions without binding auto-antibodies but with high reactivities to AQP1 peptides, which probably reflect astrocytic damage History Though the disease carries the name of József Baló, it was first described by Otto Marburg in 1906. Later, in 1928, József Baló studied the encephalitis periaxialis concentrica in a Hungarian patient, showing also demyelination of